PR Newswire·Jun 25, 2026, 2:13 PM ET

cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products

cbdMD, an NYSE American-listed company, highlights its position as a trusted hemp-derived wellness brand amid advancing federal reclassification efforts.
The White House Office of Management and Budget sent a letter to Congress urging immediate action to revise federal hemp regulations for fair treatment of compliant products.
The Administration's request emphasizes preserving access to full-spectrum CBD products while maintaining restrictions on items posing health risks.
Officials called for a responsible federal framework or an extension of the current implementation timeline to ensure policymakers have adequate time to finalize rules.
CEO Ronan Kennedy stated that the company supports science-backed, responsible hemp products and welcomes a regulatory framework that promotes safety & transparency.
Major U.S. exchanges are beginning to permit listings for compliant cannabis operators, signaling growing market legitimacy & regulatory maturity in the cannabinoid sector.
cbdMD believes its established national distribution & exchange listing position it well to capitalize on the category's evolution toward greater clarity.
The company's portfolio includes brands such as Bluebird Botanicals, Paw CBD, ATRx Labs, & the Oasis line of hemp-derived THC beverages.
Forward-looking statements in the release warn of risks regarding potential legislative delays, adverse regulation, & the impact of statutory changes to the hemp definition effective November 12, 2026.